Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
about
Advances in the treatment of invasive neonatal candidiasisPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsSafety and pharmacokinetics of repeat-dose micafungin in young infants.Pharmacokinetics of an elevated dosage of micafungin in premature neonates.Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles.Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosisEfficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.Micafungin.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patientsUse of quantitative real-time PCR to study the kinetics of extracellular DNA released from Candida albicans, with implications for diagnosis of invasive Candidiasis.Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.Management of neonatal candidiasis. Neonatal Candidiasis Study GroupCharacterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.New methods to assess susceptibilities of Aspergillus isolates to caspofungin.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisIn vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Recommendations for the treatment of fungal pneumonias.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsSteady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsAntifungal pharmacokinetics and pharmacodynamicsClinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Altered Micafungin Pharmacokinetics in Intensive Care Unit PatientsMicafungin: pharmacology, experimental therapeutics and clinical applications.Micafungin: the US perspective.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.Endogenous Candida endophthalmitis.Developments in the treatment of candidiasis: more choices and new challenges.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Antifungal prophylaxis following reduced-intensity stem cell transplantation.Micafungin: a new echinocandin antifungal.The echinocandins.
P2860
Q27022585-A32CFAD9-7B7E-4AD2-B855-05678A8EDEF7Q27025299-E4316157-A323-43DE-8420-BB053C481830Q30433612-9ED62063-E3E8-4B9A-B5C0-B9D43EAA6DBBQ30436332-5D68BB47-E989-4A72-8C10-54A05E1CFF61Q33405082-3730D04F-1BF7-41D0-9EFA-AE4969620510Q33722115-F832B392-DE23-4492-B554-6F2D57EEB044Q33769712-8CF6099D-35B6-438D-9771-99425617BC28Q33770019-8494BA97-498A-4D0D-994F-123BD1272344Q33938201-9B7B4A23-B5C3-4A8B-AEA6-1A013ED43D3DQ33980499-F7F7E720-5692-443A-AFD5-16FD2ECE7B77Q33981019-767181A8-69EC-4697-97D1-D7183F6368CEQ34045450-06E7848B-E90C-4FD8-8BD8-B248EA48277FQ34315530-3CD39FCA-91D0-475D-A7DC-491309851124Q34368144-974807E9-2CE5-458C-A847-7196CDD59374Q34680771-F490C14E-44F0-4648-9917-DE7D18458D0EQ34719835-F9933D01-18F6-40CF-B529-93E2C02B529AQ34768471-DDA1C1E3-2E14-48E5-940E-605D7508E81FQ34956645-FE39F954-F88A-45B1-BA26-3BB907DD2D36Q35026516-FC5B769D-51DB-48D1-A93B-DC68C833BF05Q35091285-3C7CC835-2E10-4E1A-9252-08DCE03D7066Q35105763-3A901ABD-D261-4C47-BA7E-7D0CEC0926FBQ35183728-A23B94CB-0CF3-4AFB-8955-60117426EFCBQ35185757-58DD3372-61E3-42FE-BE65-2CB0CF11273AQ35270758-1FA40FC8-A323-4562-AFD0-D43472930539Q35635928-01BE900C-0D37-4BA1-B646-894C9C9B6669Q35663841-37B47014-CD56-4770-944A-82ED0B2F5C4CQ35738800-5B3E342F-11E8-4247-A74F-0BA435859FDDQ35745822-CB3CE9BD-60EB-4ACC-93EF-3198E216894BQ35860004-D39E7F06-10B0-4C4A-B1D7-BAA37F1BC27FQ36120798-BF257943-A2CB-4A60-9B05-786F4E8F4F9FQ36140652-3A751F55-B56F-4AEB-9D35-7EFCF77870D1Q36425025-B67D2B8E-9741-403F-8BFA-59D0E5C13706Q36441524-1731AEBC-705C-422B-8FB6-112915BAC3D6Q36505301-28059BDE-C0C4-4D1C-9B51-29372828ECB8Q36607424-4B1C2F5B-5549-426E-B4D6-A30FE4485C48Q36623050-5964B35A-6409-4BB3-9021-7A3E17220C18Q36626518-F2B80E79-D9B2-4A4A-ADB8-22BBA3BA5266Q36658236-FC44523A-A470-4E4E-9AAC-D80E61F18415Q36693843-F95DD020-2C60-4C13-8BA1-E50FA1E23545Q36742397-93EBB074-53A1-4584-84DE-C11EBC047A72
P2860
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Comparative antifungal activit ...... sistently neutropenic rabbits.
@ast
Comparative antifungal activit ...... sistently neutropenic rabbits.
@en
Comparative antifungal activities and plasma pharmacokinetics of micafungin
@nl
type
label
Comparative antifungal activit ...... sistently neutropenic rabbits.
@ast
Comparative antifungal activit ...... sistently neutropenic rabbits.
@en
Comparative antifungal activities and plasma pharmacokinetics of micafungin
@nl
prefLabel
Comparative antifungal activit ...... sistently neutropenic rabbits.
@ast
Comparative antifungal activit ...... sistently neutropenic rabbits.
@en
Comparative antifungal activities and plasma pharmacokinetics of micafungin
@nl
P2093
P2860
P1476
Comparative antifungal activit ...... sistently neutropenic rabbits.
@en
P2093
Andreas H Groll
Caron A Lyman
Ihor Bekersky
John Bacher
Kristin Roussillon
Melissa Hemmings
Ruta Petraitiene
Thomas J Walsh
Vidmantas Petraitis
P2860
P304
P356
10.1128/AAC.46.6.1857-1869.2002
P407
P577
2002-06-01T00:00:00Z